MANNHEIM, Germany & HORSHAM, Pa.--(BUSINESS WIRE)--BioGeneriX AG, a member of the ratiopharm Group of companies, and Neose Technologies, Inc. (NasdaqGM:NTEC - News) today announced the initiation of dosing in a Phase 2 trial to evaluate the safety and efficacy of GlycoPEG-GCSF for the treatment of neutropenia associated with myelosuppressive chemotherapy. GlycoPEG-CGSF is being co-developed by the two companies.
